SEC Company Response from Keros Therapeutics, Inc. (KROS) (CIK 0001664710) (KROS) — Nov 10, 2020
Keros Therapeutics, Inc. (KROS) (CIK 0001664710)
Date: Nov. 10, 2020 · CIK: 0001664710 · Accession: 0001628280-20-016209
AI Filing Summary & Sentiment
File numbers found in text: 333-250010
Letter
Document
KEROS THERAPEUTICS, INC.
99 Hayden Avenue, Suite 120, Building E
Lexington, Massachusetts 02421
November 10, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Laura Crotty
RE:
Keros Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-250010
Acceleration Request
Requested Date: Thursday, November 12, 2020
Requested Time: 4:00 p.m. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, Keros Therapeutics, Inc. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-1 to become effective on Thursday, November 12, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant’s counsel may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes each of Ryan Sansom and Brandon Fenn of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Ryan Sansom of Cooley LLP, counsel to the Registrant, at (617) 937-2335, or in his absence, Brandon Fenn at (212) 479-6626.
[Signature Page Follows]
Very truly yours,
KEROS THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm Document KEROS THERAPEUTICS, INC. 99 Hayden Avenue, Suite 120, Building E Lexington, Massachusetts 02421 November 10, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Laura Crotty RE: Keros Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-250010 Acceleration Request Requested Date: Thursday, November 12, 2020 Requested Time: 4:00 p.m. Eastern Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, Keros Therapeutics, Inc. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-1 to become effective on Thursday, November 12, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant’s counsel may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes each of Ryan Sansom and Brandon Fenn of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Ryan Sansom of Cooley LLP, counsel to the Registrant, at (617) 937-2335, or in his absence, Brandon Fenn at (212) 479-6626. [Signature Page Follows] Very truly yours, KEROS THERAPEUTICS, INC. By: /s/ Jasbir Seehra Name: Jasbir Seehra, Ph.D. Title: Chief Executive Officer cc: Esther Cho, Keros Therapeutics, Inc. Marc A. Recht, Cooley LLP Ryan S. Sansom, Cooley LLP Brandon Fenn, Cooley LLP Peter N. Handrinos, Latham & Watkins LLP Nathan Ajiashvili, Latham & Watkins LLP